Prediction of near-future HbA1c levels using glycated albumin levels before and after glimepiride administration for 2 weeks is useful to determine the effectiveness of the treatment

Diabetology International

Volumn 3, Issue 4, 2012, Pages 197-201

  Koga, Masafumi ^a   Murai, Jun ^a   Saito, Hiroshi ^a   Kasayama, Soji ^b  

^a Kinki Central Hospital of Mutual Association of Public School Teachers   (Japan)

^b Nissay Hospital   (Japan)

Author keywords

Glimepiride; Glycated albumin; HbA1c; Type 2 diabetes

Indexed keywords

GLIMEPIRIDE; GLYCOSYLATED ALBUMIN; HEMOGLOBIN A1C; METFORMIN;

ADD ON THERAPY; ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL DECISION MAKING; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84871278693     PISSN: 21901678     EISSN: 21901686     Source Type: Journal    
DOI: 10.1007/s13340-012-0075-x     Document Type: Article

References (21)

1. Cohen MP. Nonenzymatic glycation: a central mechanism in diabetic microvasculopathy? J Diabet Complications. 1998; 2: 214-7.
2. Koenig RJ, Peterson CM, Jones RL, Saudek C, Lehrman M, Cerami A. Correlation of glucose regulation and hemoglobin A1c in diabetes mellitus. N Engl J Med. 1978; 295: 417-20.
3. Bunn HF, Gabbay KH, Gallop PM. The glycosylation of hemoglobin: relevance to diabetes mellitus. Science. 1978; 20: 21-7.
4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329: 977-86.
5. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32: 193-203.
6. Koga M, Kasayama S. Clinical impact of glycated albumin as another glycemic control marker. Endocr J. 2010; 57: 751-62.
7. Tahara Y, Shima K. Kinetics of HbA1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. Diabetes Care. 1995; 18: 440-7.
8. Iberg N, Fluckiger R. Nonenzymatic glycosylation of albumin in vivo. Identification of multiple glycosylated sites. J Biol Chem. 1986; 261: 13542-5.
9. Takahashi S, Uchino H, Shimizu T, Kanazawa A, Tamura Y, Sakai K, Watada H, Hirose T, Kawamori R, Tanaka Y. Comparison of glycated albumin (GA) and glycated hemoglobin (HbA1c) in type 2 diabetic patients: usefulness of GA for evaluation of short-term changes in glycemic control. Endocr J. 2007; 54: 139-44.
10. Yoshiuchi K, Matsuhisa M, Katakami N, Nakatani Y, Sakamoto K, Matsuoka T, Umayahara Y, Kosugi K, Kaneto H, Yamasaki Y, Hori M. Glycated albumin is a better indicator for glucose excursion than glycated hemoglobin in type 1 and type 2 diabetes. Endocr J. 2008; 55: 503-7.
11. Koga M, Murai J, Saito H, Kasayama S. Glycated albumin and glycated hemoglobin are differently influenced by endogenous insulin secretion in patients with type 2 diabetes mellitus. Diabetes Care. 2010; 33: 270-2.
12. Koga M, Hashimoto K, Murai J, Saito H, Mukai M, Ikegame K, Ogawa H, Kasayama S. Usefulness of glycated albumin as an indicator of glycemic control status in patients with hemolytic anemia. Clin Chim Acta. 2011; 412: 253-7.
13. Inaba M, Okuno S, Kumeda Y, Yamada S, Imanishi Y, Tabata T, Okamura M, Okada S, Yamakawa T, Ishimura E. Expert Research Group. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol. 2007; 18: 896-903.
14. Koga M, Murai J, Saito H, Kasayama S. Prediction of near-future glycated hemoglobin levels using glycated albumin levels before and after treatment for diabetes. J Diabetes Invest. 2011; 2: 304-9.
15. Hamaguchi T, Koga M, Murai J, Saito H, Tamada D, Kurebayashi S, Katsuno T, Miyagawa J, Namba M. Estimation of HbA1c response to sitagliptin by change in glycated albumin level for two weeks. J Diabetes Invest. 2012; 3: 175-8.
16. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med. 2008; 359: 1565-76.
17. Koga M, Otsuki M, Kubo M, Hashimoto J, Kasayama S. Relationship between circulating vascular cell adhesion molecule-1 and microvascular complications in type 2 diabetes mellitus. Diabet Med. 1998; 15: 661-7.
18. Schnedl WJ, Lahousen T, Wallner SJ, Krause R, Lipp RW. Silent hemoglobin variants and determination of HbA1c with the high-resolution program of the HPLC HA-8160 hemoglobin analyzer. Clin Biochem. 2005; 38: 88-91.
19. The Committee of Japan Diabetes Society on the Diagnostic Criteria of Diabetes mellitus. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest. 2010; 1: 212-28.
20. Kouzuma T, Usami T, Yamakoshi M, Takahashi M, Imamura S. An enzymatic method for the measurement of glycated albumin in biological samples. Clin Chim Acta. 2002; 324: 61-71.
21. Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab. 2005; 90: 501-6.